Pérez CAE, Guerra CE, Rodríguez AOD

Language: Spanish
References: 34
Page: 235-246
PDF size: 322.37 Kb.

ABSTRACT

Advances in the cellular and molecular biology have allowed a better understanding of the meaning of cancer. Many researchers agree about an orderly and sequential occurrence of tumor progression in each of the most frequent human tumors, the presence of "gatekeeper and caretaker genes" that regulate the sense of this development, the adaptative nature of the mutations underlying carcinogenesis, among others. It seems that induced genetic variability and genetic polymorphism influence decisively the susceptibility for the onset of neoplasia.

REFERENCES

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30

2. Yan H, Kinzler KW, Vogelstein B. Genetic Testing– Present and Future. Science. 2000;289(5486):1890-2.

3. Strausberg RL, Greenhut SF, Grouse LH, Schaefer CF, Buetow KH. In silico analysis of cancer through the Cancer Genome Anatomy Proyect. Trends Cell Biol. 2001; 11(11):66-71.

4. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular Classification of Cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531-7.

5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9(4):138-41.

6. Munger K. Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest. 2002;20(1):71-81.

7. Tobias ES, Connor M, Ferguson Smith M. The molecular biology of cancer. En: Rimoin DL, Connor JM, Pyeritz RE, Korf BR. Emery and Rimoin´s Principles and Practices of Medical Genetics. 5 ed. New York: Churchill Livingston;2005.

8. Mc Donell TJ, Beham A, Sarkiss M, Andersen MM, Lo P. Importance of the Bcl-2 family in cell death regulation. Experientia. 1996;52(10-11):1008-17.

9. Reed JC. Double indemnity for proteins of the bcl-2 family. Nature. 1997;387:773.

10. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997;385:637-40.

11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 18;87(2):159-70.

12. Hoops TC, Traber PG. Molecular pathogenesis of colorectal cancer. Hematol Oncol Clin North Am. 1997;11(4):609-33.

13. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004;9(4): 371-77.

14. Kinzler KW, Volgenstein B. Gatekeeper and caretakers. Nature 1997;386(6627): 761-63.

15. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991;51(12):3075-9.

16. Denissenko MF, Pao A, Tang MS, Pfeifer GP. Preferential formation of benzo-apyrene adducts at lung cancer mutational hotspots in p53. Science. 1996; 274(5286):430-2.

17. Boyd MT, Vlatkovic N. P53: a molecular marker for the detection of cancer. Expert Opin Med Diagn. 2008;2(9):1013-24.

18. Crespi B, Summers K. Evolutionary biology of cancer. Trends Ecol Evol. 2005; 20(10):545-52.

19. Baranczewski P, Möller L. Relationship between content and activity of cytochrome P450 and induction of heterocyclic amine DNA adducts in human liver samples in vivo and in vitro. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1071-8.

20. Perera FP. Environment and cancer: Who are susceptible? Science. 1997; 278(5340):1068-73.

21. Vineis P. Molecular epidemiology: low dose carcinogens and genetic susceptibility. Int J Cancer. 1997;71(1):1-3.

22. Gimbrone MA, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 1997;100(Supl. 1):61-5.

23. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279(5349):349-52.

24. Balasubramanian S, Singh N. Telomeres and telomerase in human cancer. Indian J Physiol Pharmacol. 1996;40(3):199-204.

25. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomerase length in human tumors and tumor-derived cell lines. Nat Med. 1997;3(11):1271-4.

26. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007;21(11):1367-81.

27. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.

28. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57.

29. Hanahan D, Folkman J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):335-64.

30. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:1-100.

31. Liotta WR. The hallmark of antimetastatics genes. En: DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. 7 ed. Philadelphia: Lippincott-Raven;2005. p. 198.

32. Yuspa SH, Shields PG. Etiology of cancer: Chemical factors. En: DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. 7 ed. Philadelphia: Lippincott-Raven;2005. p. 571.

33. Mastrangelo G, Fadda E, Marzia V. Policyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect. 1996;104(11):1166-70.

34. Robbins, Contran. Patología estructural y funcional. 7 ed. Madrid: Elsevier; 2005.